About this trial
This prospective observational study aims to investigate whether serum REST4 concentration can serve as a quantitative indicator correlated with abdominal aortic aneurysm (AAA) diameter and a predictive biomarker for AAA progression and rupture risk. Emerging evidence suggests that REST4, a splice variant of the RE-1 Silencing Transcription Factor (REST), is upregulated in vascular smooth muscle cells during AAA pathogenesis and may be released into circulation via exosomes. The study will enroll patients with asymptomatic AAA (diameter between 39-49 mm) and measure baseline serum REST4 levels, analyzing their association with morphological severity (maximum aortic diameter) and clinical outcomes (aneurysm growth rate, rupture and related mortality) through a 5-year follow-up period.
Eligibility criteria
Qualifiers
Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;
Han nationality;
Between 50 years or more, no gender limit;
No mental illness;
Disqualifiers
Previous infrarenal aortic surgery;
Planned major surgery;
Known aortic dissection;
Have received any other clinical trial treatment within 1 year;
Trial design
Treatments tested in this trial
- mRNA level of REST4 in serum;